Arbidol (umifenovir) / Pharmstandard - LARVOL DELTA

Discovery of a novel broad-spectrum inhibitor against influenza virus A. (PubMed, Virol J) - "Arbidol, an effective pharmaceutical against IAV and other viruses, inhibits viral fusion by targeting a conserved binding region across multiple virus types...The molecular structure of Glycyrrhetinic acid is more flexible, which avoids significant interactions with hERG. These findings highlight glycyrrhetinic acid as a promising broad-spectrum anti-IAV candidate drug."

Journal • Cardiovascular • Infectious Disease • Influenza • Respiratory Diseases

The Efficacy and Safety of Arbidol in Reducing the Frequency of AECOPD. (clinicaltrials.gov) - P4 | N=351 | Completed | Sponsor: Shengjing Hospital | Enrolling by invitation ➔ Completed | N=990 ➔ 351

Enrollment change • Trial completion • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Mechanistic insights into the small-molecule inhibition of influenza A virus entry. (PubMed, Proc Natl Acad Sci U S A) - "Structure-guided mutagenesis confirmed the critical roles of key interacting residues and uncovered distinct resistance profiles between the two compounds, as well as in comparison to Arbidol, a previously reported HA inhibitor...To address this, we propose an alternative strategy for broadening antiviral coverage. Together, these findings provide mechanistic insights into IAV entry inhibition and a foundation for the rational design of next-generation anti-influenza therapeutics."

Journal • Infectious Disease • Influenza • Respiratory Diseases

Bioequivalence of arbidol hydrochloride tablets in a randomized, open, two-agent, single-dose, three-cycle fasting trial in healthy subjects (ChiCTR) - P1 | N=36 | Completed | Sponsor: The Second Hospital of Hebei Medical University; The Second Hospital of Hebei Medical University

New P1 trial

Clinical Evaluation of Umifenovir as a Potential Antiviral Therapy for COVID-19: A Multi-center, Randomized, Controlled Clinical Trial. (PubMed, Oman Med J) - "While umifenovir exhibited some immunological benefits in COVID-19 patients, it did not significantly improve broader patient-important outcomes compared to standard care. Therefore, its routine use in clinical practice for COVID-19 treatment is currently not justified, highlighting the need for further research to explore alternative therapeutic strategies."

Clinical • Journal • Critical care • Infectious Disease • Musculoskeletal Pain • Novel Coronavirus Disease • Pain

Supercomputing Multi-Ligand Modeling, Simulation, Wavelet Analysis and Surface Plasmon Resonance to Develop Novel Combination Drugs: A Case Study of Arbidol and Baicalein Against Main Protease of SARS-CoV-2. (PubMed, Pharmaceuticals (Basel)) - " HQA004 demonstrated synergistic potential with arbidol in inhibiting Mpro. The development of combination therapies integrating Western and herbal medicine is supported by these findings for effective antiviral treatments."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

On degree-dependent topological study of line graph of some antiviral COVID-19 drugs. (PubMed, Eur Phys J E Soft Matter) - "This article focuses on the topological characterization of a line graph for antiviral COVID-19 drugs, namely Nirmatrelvir, Molnupiravir, Thalidomide, Theaflavin, Remdesivir, Ritonavir, Chloroquine, Hydroxychloroquine, Arbidol and Lopinavir. A comparison is made between the squared correlation coefficients derived from our curvilinear regression models and those obtained from earlier research. These findings may aid the applicability of newly developed drugs of similar kind, in predicting their physicochemical properties and in improving the associated QSPR studies and hence pave a way to improve treatments against the COVID-19 disease."

Journal • Infectious Disease • Novel Coronavirus Disease

Hemagglutinin docking analysis-based visual detection of antiviral therapeutic efficacy of umifenovir against influenza virus. (PubMed, Biosens Bioelectron) - "Additionally, the aggregation of umi-GNPs with viruses pre-bound to umifenovir was suppressed, indicating that umi-GNPs bind to a specific region of the viral protein. These findings indicate that umi-GNPs can serve as novel agents for visually determining umifenovir resistance in IAV."

Journal • Infectious Disease • Influenza • Respiratory Diseases

COVID-19 management in patients with comorbid conditions. (PubMed, World J Virol) - "Antiviral agents like Remdesivir, an adenosine nucleotide analog, inhibit viral RNA polymerase and have shown efficacy in reducing COVID-19 severity, leading to its emergency use authorization for hospitalized patients. Other antivirals like ritonavir, lopinavir, and umifenovir disrupt viral replication and entry, but their effectiveness against SARS-CoV-2 remains under investigation. Dexamethasone, a corticosteroid, has been used in critically ill COVID-19 patients to reduce inflammation and prevent respiratory failure, as shown in the RECOVERY trial. Other immunosuppressants like ruxolitinib, baricitinib, and colchicine help modulate the immune response, reducing cytokine storms and inflammation-related complications...Systematic reviews of clinical studies revealed that hydroxychloroquine with or without azithromycin did not decrease viral load nor reduce the severity of symptoms, but increased mortality among acutely hospitalized patients...Monoclonal antibodies like..."

Journal • Review • Acute Lung Injury • Acute Respiratory Distress Syndrome • Cardiovascular • Chronic Kidney Disease • Chronic Obstructive Pulmonary Disease • Diabetes • Ebola Virus Disease • Genetic Disorders • Heart Failure • Immunology • Infectious Disease • Inflammation • Metabolic Disorders • Nephrology • Novel Coronavirus Disease • Obesity • Pulmonary Disease • Renal Disease • Respiratory Diseases

STAR: Severe Influenza Trial of ARbidol (clinicaltrials.gov) - P3 | N=200 | Completed | Sponsor: Capital Medical University | Unknown status ➔ Completed | Trial completion date: Aug 2020 ➔ Oct 2024

Trial completion • Trial completion date • Infectious Disease • Influenza • Respiratory Diseases

Antiviral therapy for influenza in high-risk outpatients: a multicenter observational study of routine clinical practice in Russia. (PubMed, Ther Adv Infect Dis) - "The study was conducted during the 2023-2024 influenza epidemic season and included 1867 high-risk outpatients treated with oseltamivir, umifenovir, kagocel, or imidazolyl ethanamide pentanedioic acid. The etiotropic agents oseltamivir and umifenovir demonstrated comparable efficacy in managing influenza in high-risk patients, as reflected by their impact on bacterial complication rates and disease duration. Both drugs may be recommended for the treatment of high-risk influenza patients."

Journal • Observational data • Allergy • Gastroenterology • Gastrointestinal Disorder • Infectious Disease • Influenza • Respiratory Diseases

Antimicrobial Prescribing Patterns in Russian Outpatients in 2024: Results of the Global-PPS Project. (PubMed, Infect Chemother) - "The pooled rates of antimicrobial prescribing in outpatient settings was 9.6% with the substantial differences in patterns of consumption overall and among the units of different types. Broad-spectrum antibacterials such as penicillin/beta-lactamase inhibitor combinations, III-IV generation cephalosporins, fluoroquinolones, and macrolides together amounted to 48% of prescriptions. Common concerns in antimicrobial drug usage included low guidelines compliance and low rate of "access" group antibacterials."

Journal • Gastroenterology • Gynecology • Hematological Disorders • KRAS

Drug treatments for mild or moderate covid-19: systematic review and network meta-analysis. (PubMed, BMJ) - "Nirmatrelvir-ritonavir and remdesivir probably reduce admission to hospital, and systemic corticosteroids and molnupiravir may reduce admission to hospital. Several medications including systemic corticosteroids and molnupiravir probably reduce time to symptom resolution."

Clinical • Journal • Retrospective data • Review • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

QSPR modeling of some COVID-19 drugs using neighborhood eccentricity-based topological indices: A comparative analysis. (PubMed, PLoS One) - "In this paper, we consider recently used drugs such as arbidol, chloroquine, hydroxy-chloroquine, lopinavir, remdesivir, ritonavir, thalidomide and theaflavin in treatment of COVID-19. The results show that topological indices and applied regression models are useful in predicting significant characteristics of drugs used for the treatment of COVID-19. Additionally, a comparison of the known values and the calculated values from the regression models discussed is obtained."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Efficacy and Safety of Arbidol in the Treatment of Allergic Rhinitis (clinicaltrials.gov) - P=N/A | N=15 | Recruiting | Sponsor: Zheng Liu | Not yet recruiting ➔ Recruiting

Enrollment open • Allergic Rhinitis • Immunology • Inflammation

Strategic Design and Optimization of Umifenovir Analogues: Balancing Antiviral Efficacy and hERG Toxicity against SARS-CoV-2. (PubMed, J Med Chem) - "C3 modifications led to lead compounds 77, 79, and 81 (IC50 = 0.67-0.7 μM), achieving superior potency while eliminating hERG toxicity. Mechanism of entry inhibition and immunofluorescence confirmed compound 77 significantly reduced SARS-CoV-2 within Vero cells, supporting their preclinical potential."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Design, Synthesis and Anti-Influenza Virus Activity of 4-Tert-Butyl-N-(3-Oxo-1-Thia-4-Azaspiro[4.5]Dec-4-yl)Benzamide Derivatives That Target Hemagglutinin-Mediated Fusion. (PubMed, Drug Dev Res) - "Computer-aided docking was performed to predict the possible binding pocket in the H3 HA trimer. Resistance data and in silico studies indicated that compound 2c has an overlapping binding pocket in the stem region of H3 HA with the known fusion inhibitors TBHQ and arbidol."

Journal • Infectious Disease • Influenza • Respiratory Diseases

Antiviral Medications for Treatment of Nonsevere Influenza: A Systematic Review and Network Meta-Analysis. (PubMed, JAMA Intern Med) - "All antiviral drugs (no data for peramivir and amantadine) had little or no effect on hospital admission for low-risk patients (high certainty)...For time to alleviation of symptoms, baloxavir probably reduced symptom duration (mean difference [MD], -1.02 days; 95% CI, -1.41 to -0.63; moderate certainty); umifenovir may have reduced symptom duration (MD, -1.10 days; 95% CI, -1.57 to -0.63; low certainty); oseltamivir probably had no important effect (MD, -0.75 days; 95% CI, -0.93 to -0.57; moderate certainty)...This systematic review and meta-analysis found that baloxavir probably reduced risk of hospital admission for high-risk patients and may reduce time to alleviation of symptoms, without increasing adverse events related to treatment in patients with nonsevere influenza. All other antiviral drugs either probably have little or no effect, or uncertain effects on patient-important outcomes."

Clinical • Journal • Retrospective data • Critical care • Infectious Disease • Influenza • Respiratory Diseases

A Glimpse for the subsistence from pandemic SARS-CoV-2 infection. (PubMed, Bioorg Chem) - "Although some drug regimens and vaccines have shown safety in trials, none have been entirely successful yet. This review highlights, some of the potential antibodies (tocilizumab, Sarilumab, Avdoralimab, Lenzilumab, Interferon (alfa /beta /gamma)) screened against SARS-CoV-2 and the most promising drugs (Favipiravir, Hydroxychloroquine, Niclosamide, Ribavirin, Baricitinib, Remdesivir, Arbidol Losartan, Ritonavir, Lopinavir, Baloxavir, Nitazoxanide, Camostat) in various stages of development with their synthetic protocol and their clinical projects are discussed to counter COVID -19."

Journal • Review • Cardiovascular • Gastrointestinal Disorder • Infectious Disease • Nephrology • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases

CYCL-NTTF-2023: Study of Safety and Efficacy of the Drug Cycloferone in Patients with Acute Respiratory Viral Infection (clinicaltrials.gov) - P=N/A | N=742 | Completed | Sponsor: POLYSAN Scientific & Technological Pharmaceutical Company | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease

Recent report on indoles as a privileged anti-viral scaffold in drug discovery. (PubMed, Eur J Med Chem) - "Indole-containing drugs, such as enfuvirtide (T-20), arbidol, and delavirdine, have demonstrated significant efficacy in treating viral diseases. The review includes discussions on synthetic protocols, inhibitory concentrations, SAR study, and computational study. This review shall identify new antiviral indoles that may help to combat new viral threats in the future."

Journal • Review • Dengue Fever • Ebola Virus Disease • Hepatology • Human Immunodeficiency Virus • Infectious Disease • Inflammation • Influenza • Novel Coronavirus Disease • Respiratory Diseases

Dominance of Dengue Virus Serotype-2 in Pakistan (2023-2024): Molecular Characterization of the Envelope Gene and Exploration of Antiviral Targets. (PubMed, Virus Res) - "Computational modeling of the envelope protein structure identified potential antiviral binding sites and further molecular docking studies suggested that specific antiviral compounds like Arbidol and Quercetin can inhibit early steps in viral infection. Additionally, BepiPred-3.0 predicted several B-cell epitopes, which could be useful for vaccine development. These findings enhance our understanding of dengue epidemiology in Pakistan and contribute to the development of targeted antiviral therapies, potentially informing future vaccination strategies and outbreak management."

Journal • Dengue Fever • Hematological Disorders • Infectious Disease

A fast solid-phase microextraction scheme for in vivo monitoring of bio-accumulation and bio-transformation of arbidol in living plants. (PubMed, Sci Total Environ) - "Additionally, the plant root secretion was found to be significantly altered by arbidol exposure. To summarized, the combination of in vivo SPME and the FT-ICR-MS analysis provide new and important information regarding arbidol contamination and related alternation of plant root metabolism."

Journal • Preclinical • Infectious Disease • Influenza • Novel Coronavirus Disease • Respiratory Diseases

PREGNANCY OUTCOMES IN THE ETRASIMOD CLINICAL PROGRAMME (UEGW 2024) - "Pregnancy outcomes during the etrasimod clinical development programmeFoetal deathCongenital malformationSpontaneous abortionHealthy newbornMedical terminationLost to follow-upMaternalexposure, n (%)(N = 9)01 (11.1)a1 (11.1)2 (22.2)b4 (44.4)c,d,e1 (11.1)fPaternalexposure, n (%)(N = 5)002 (40.0)2 (40.0)01 (20.0)Data on pregnancy events and outcomes were taken from the Pfizer internal data warehouse on serious adverse events that included pregnancy.aPremature 34-week delivery due to premature rupture of membranes, open (patent) foramen ovale (heart) with circulatory failure and transient tachypnoea of the newborn, which were all considered non-serious concomitant events.bBoth patients had full-term birth, caesarean delivery.cReasons for medical termination were not known in two cases.dOne patient with an anembryonic gestation where umifenovir (received for a respiratory tract infection) was a co-suspected drug. Few pregnancies have been reported in the etrasimod clinical..."

Clinical • Alopecia • Atopic Dermatitis • Crohn's disease • Dermatitis • Dermatology • Eosinophilic Esophagitis • Gastroenterology • Gastrointestinal Disorder • Infectious Disease • Inflammatory Bowel Disease • Long-acting Reversible Contraceptives • Respiratory Diseases • Ulcerative Colitis

Comparative assessment of the clinical effectiveness of direct-acting antiviral drugs in outpatient patients with acute respiratory viral infections (PubMed, Ter Arkh) - "The use of direct antiviral drugs contributes to the rapid relief of ARVI symptoms in patients receiving medical care on an outpatient basis. The antiviral drug riamilovir showed the most pronounced effectiveness (clinical and laboratory)."

Clinical • Journal • Cough • Gene Therapies • Infectious Disease • Inflammation • Pain • Respiratory Diseases